JP7546603B2 - タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 - Google Patents
タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 Download PDFInfo
- Publication number
- JP7546603B2 JP7546603B2 JP2021568650A JP2021568650A JP7546603B2 JP 7546603 B2 JP7546603 B2 JP 7546603B2 JP 2021568650 A JP2021568650 A JP 2021568650A JP 2021568650 A JP2021568650 A JP 2021568650A JP 7546603 B2 JP7546603 B2 JP 7546603B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- ripk3
- pyrimidin
- yield
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010099 disease Diseases 0.000 title description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 19
- 239000003909 protein kinase inhibitor Substances 0.000 title description 7
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 59
- 241000712431 Influenza A virus Species 0.000 claims description 54
- 108091000080 Phosphotransferase Proteins 0.000 claims description 38
- 102000020233 phosphotransferase Human genes 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 31
- 230000002757 inflammatory effect Effects 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- -1 carrier Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims 3
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
- 239000007787 solid Substances 0.000 description 127
- 239000003112 inhibitor Substances 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 67
- 235000019439 ethyl acetate Nutrition 0.000 description 63
- 239000011541 reaction mixture Substances 0.000 description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 54
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 230000021597 necroptosis Effects 0.000 description 29
- 238000004440 column chromatography Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 102000001253 Protein Kinase Human genes 0.000 description 26
- 108060006633 protein kinase Proteins 0.000 description 26
- 229910052786 argon Inorganic materials 0.000 description 25
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 230000030833 cell death Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 102000003390 tumor necrosis factor Human genes 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000007832 Na2SO4 Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 8
- 208000004852 Lung Injury Diseases 0.000 description 8
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 206010069363 Traumatic lung injury Diseases 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 231100000515 lung injury Toxicity 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- HCYCPZFHVYEOER-UHFFFAOYSA-N 6-bromo-N-(3-methylsulfonylphenyl)quinazolin-2-amine Chemical compound BrC=1C=C2C=NC(=NC2=CC=1)NC1=CC(=CC=C1)S(=O)(=O)C HCYCPZFHVYEOER-UHFFFAOYSA-N 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 229910052593 corundum Inorganic materials 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 229910001845 yogo sapphire Inorganic materials 0.000 description 7
- DMYSBMDUVXRMJU-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C DMYSBMDUVXRMJU-UHFFFAOYSA-N 0.000 description 6
- KBFYJXMMAXTGQP-UHFFFAOYSA-N 6-chloro-4-(methylamino)pyridine-3-carbaldehyde Chemical compound CNC1=CC(Cl)=NC=C1C=O KBFYJXMMAXTGQP-UHFFFAOYSA-N 0.000 description 6
- QWYRMGYQWFJVTO-UHFFFAOYSA-N 6-chloro-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC2=C(N=C(N=C2)SC)N(C1=O)C QWYRMGYQWFJVTO-UHFFFAOYSA-N 0.000 description 6
- JUTMBPHYBCRASJ-UHFFFAOYSA-N 7-chloro-3-(2-chlorophenyl)-1-methyl-1,6-naphthyridin-2-one Chemical compound ClC1=NC=C2C=C(C(N(C2=C1)C)=O)C1=C(C=CC=C1)Cl JUTMBPHYBCRASJ-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 125000006414 CCl Chemical group ClC* 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- YVBIXOXCIOUBMY-UHFFFAOYSA-N [6-chloro-4-(methylamino)pyridin-3-yl]methanol Chemical compound CNC1=CC(Cl)=NC=C1CO YVBIXOXCIOUBMY-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000001338 necrotic effect Effects 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WGUCZWYLSKPURM-UHFFFAOYSA-N 4-(methylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CNC1=NC(SC)=NC=C1C=O WGUCZWYLSKPURM-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000006721 cell death pathway Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 4
- FGONQMFYFJRAIG-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(N)=N1 FGONQMFYFJRAIG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- IKWPXQBMCNBGEG-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C IKWPXQBMCNBGEG-UHFFFAOYSA-N 0.000 description 4
- SVBLFAQKAOTDFU-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C SVBLFAQKAOTDFU-UHFFFAOYSA-N 0.000 description 4
- NYQBZJFZEZEXFP-UHFFFAOYSA-N 6-bromo-2-chloroquinazoline Chemical compound C1=C(Br)C=CC2=NC(Cl)=NC=C21 NYQBZJFZEZEXFP-UHFFFAOYSA-N 0.000 description 4
- DHKLJXPNLNWRLZ-UHFFFAOYSA-N 6-bromo-N-[4-[2-(diethylamino)ethoxy]phenyl]quinazolin-2-amine Chemical compound BrC=1C=C2C=NC(=NC2=CC=1)NC1=CC=C(C=C1)OCCN(CC)CC DHKLJXPNLNWRLZ-UHFFFAOYSA-N 0.000 description 4
- SAHIBUAQEWUWBE-UHFFFAOYSA-N ClC1=NC=C2C=C(C(N(C2=C1)C)=O)C1=CC(=CC=C1)O Chemical compound ClC1=NC=C2C=C(C(N(C2=C1)C)=O)C1=CC(=CC=C1)O SAHIBUAQEWUWBE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 4
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- QINRQIZOBCQKAZ-UHFFFAOYSA-N ethyl 4-amino-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1N QINRQIZOBCQKAZ-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 231100000516 lung damage Toxicity 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- CUAUTGRQMYJPFC-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-ethyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C=CC=CC=2)C(=O)N2CC)C2=N1 CUAUTGRQMYJPFC-UHFFFAOYSA-N 0.000 description 3
- AABYCBJQCOPZML-UHFFFAOYSA-N 3-(1,1-dioxo-1,4-thiazinan-4-yl)aniline Chemical compound NC1=CC=CC(N2CCS(=O)(=O)CC2)=C1 AABYCBJQCOPZML-UHFFFAOYSA-N 0.000 description 3
- KIWPCGODBFBHFF-UHFFFAOYSA-N 3-(2-chlorophenyl)-1-methyl-7-[3-(4-methylpiperazin-1-yl)anilino]-1,6-naphthyridin-2-one Chemical compound ClC1=C(C=CC=C1)C=1C(N(C2=CC(=NC=C2C=1)NC1=CC(=CC=C1)N1CCN(CC1)C)C)=O KIWPCGODBFBHFF-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WZJSEOATGOTFNY-UHFFFAOYSA-N 4-(3-nitrophenyl)-1,4-thiazinane 1,1-dioxide Chemical compound [O-][N+](=O)C1=CC=CC(N2CCS(=O)(=O)CC2)=C1 WZJSEOATGOTFNY-UHFFFAOYSA-N 0.000 description 3
- LFJGGGIWERIGNX-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]aniline Chemical compound CCN(CC)CCOC1=CC=C(N)C=C1 LFJGGGIWERIGNX-UHFFFAOYSA-N 0.000 description 3
- AJICYMQAPFTFJW-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C AJICYMQAPFTFJW-UHFFFAOYSA-N 0.000 description 3
- XMJBSGYDACBKMY-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C XMJBSGYDACBKMY-UHFFFAOYSA-N 0.000 description 3
- WKJKSHGZNWFXCD-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound CSc1ncc2cc(-c3ccc(O)cc3)c(=O)n(C)c2n1 WKJKSHGZNWFXCD-UHFFFAOYSA-N 0.000 description 3
- OLIVQCGSZZJHAF-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound COc1ccc(cc1)-c1cc2cnc(SC)nc2n(C)c1=O OLIVQCGSZZJHAF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229910014033 C-OH Inorganic materials 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 229910014570 C—OH Inorganic materials 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CIKTYIPDZNLIDJ-UHFFFAOYSA-N N-[4-[2-(diethylamino)ethoxy]phenyl]formamide Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=O)CC CIKTYIPDZNLIDJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- VDDZMXQAZJMGPK-UHFFFAOYSA-N ethyl 4-(methylamino)-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NC VDDZMXQAZJMGPK-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- OONQSUFLXZFOLA-UHFFFAOYSA-N n-(3-methylsulfonylphenyl)formamide Chemical compound CS(=O)(=O)C1=CC=CC(NC=O)=C1 OONQSUFLXZFOLA-UHFFFAOYSA-N 0.000 description 3
- ZCDBTQNFAPKACC-UHFFFAOYSA-N n-(6-propan-2-ylsulfonylquinolin-4-yl)-1,3-benzothiazol-5-amine Chemical compound C1=C2SC=NC2=CC(NC2=CC=NC3=CC=C(C=C32)S(=O)(=O)C(C)C)=C1 ZCDBTQNFAPKACC-UHFFFAOYSA-N 0.000 description 3
- NOCSAAHHSOQRCI-UHFFFAOYSA-N n-pyridin-2-ylformamide Chemical compound O=CNC1=CC=CC=N1 NOCSAAHHSOQRCI-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- UKYCKUPXBPLXBA-UHFFFAOYSA-N (2-chloro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(Cl)=C1 UKYCKUPXBPLXBA-UHFFFAOYSA-N 0.000 description 2
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- LYUPJHVGLFETDG-UHFFFAOYSA-N 1-phenylbutan-2-ol Chemical compound CCC(O)CC1=CC=CC=C1 LYUPJHVGLFETDG-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VJARIBGMDPJLCL-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C(Cl)=C1 VJARIBGMDPJLCL-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- RJGHJWKQCJAJEP-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=CC(N)=C1 RJGHJWKQCJAJEP-UHFFFAOYSA-N 0.000 description 2
- VPCLIVPTMMWUQZ-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-imine Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=N)C VPCLIVPTMMWUQZ-UHFFFAOYSA-N 0.000 description 2
- GUOZHNHJTXGTIQ-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C GUOZHNHJTXGTIQ-UHFFFAOYSA-N 0.000 description 2
- MBFQPUZSYLGVET-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C MBFQPUZSYLGVET-UHFFFAOYSA-N 0.000 description 2
- WUEJFDOJIBRVBJ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-(2-methoxyethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CCOC WUEJFDOJIBRVBJ-UHFFFAOYSA-N 0.000 description 2
- YBDMDASOVBUGSC-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-(2-methylpropyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC(C)C YBDMDASOVBUGSC-UHFFFAOYSA-N 0.000 description 2
- LRVMKRQQVSSYSR-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C LRVMKRQQVSSYSR-UHFFFAOYSA-N 0.000 description 2
- UHSFMLWTMAUOTK-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C UHSFMLWTMAUOTK-UHFFFAOYSA-N 0.000 description 2
- KPRCKNFYMXVRCB-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(SC)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl KPRCKNFYMXVRCB-UHFFFAOYSA-N 0.000 description 2
- WLWJJKVNIOIIEU-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfonyl-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C WLWJJKVNIOIIEU-UHFFFAOYSA-N 0.000 description 2
- UDRCNOJXKFMKMD-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfonyl-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C UDRCNOJXKFMKMD-UHFFFAOYSA-N 0.000 description 2
- RSRLLINYTJHRCA-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methoxyethyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CCOC RSRLLINYTJHRCA-UHFFFAOYSA-N 0.000 description 2
- YTTDACRYINJOTE-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methoxyethyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CCOC YTTDACRYINJOTE-UHFFFAOYSA-N 0.000 description 2
- LCKCHOMHDSHDJF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl LCKCHOMHDSHDJF-UHFFFAOYSA-N 0.000 description 2
- BADVXFUKYQHVBO-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl BADVXFUKYQHVBO-UHFFFAOYSA-N 0.000 description 2
- ZOLPTXOZGBDIDY-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C ZOLPTXOZGBDIDY-UHFFFAOYSA-N 0.000 description 2
- KIHKWCNGGYKWJU-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C KIHKWCNGGYKWJU-UHFFFAOYSA-N 0.000 description 2
- DJKHWQKHUPEYFK-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C DJKHWQKHUPEYFK-UHFFFAOYSA-N 0.000 description 2
- OMLZCXJVYHKTKX-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C OMLZCXJVYHKTKX-UHFFFAOYSA-N 0.000 description 2
- GPAVSRFSJCTRBG-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1Cl GPAVSRFSJCTRBG-UHFFFAOYSA-N 0.000 description 2
- XFOWYVBQBQMUAH-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1Cl XFOWYVBQBQMUAH-UHFFFAOYSA-N 0.000 description 2
- PWQZNGLXWFPWHS-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)NC1=O PWQZNGLXWFPWHS-UHFFFAOYSA-N 0.000 description 2
- XDPFREWMZLZKEE-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC(C)C XDPFREWMZLZKEE-UHFFFAOYSA-N 0.000 description 2
- PCHATNUAXGFSIQ-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC(C)C PCHATNUAXGFSIQ-UHFFFAOYSA-N 0.000 description 2
- TWLGRDCGDNJMOF-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C TWLGRDCGDNJMOF-UHFFFAOYSA-N 0.000 description 2
- UXONUTCSTCAEAZ-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound COC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C UXONUTCSTCAEAZ-UHFFFAOYSA-N 0.000 description 2
- OBAFTXSPHNOIGT-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound CSc1ncc2cc(-c3ccc(cc3)C(C)(C)C)c(=O)n(C)c2n1 OBAFTXSPHNOIGT-UHFFFAOYSA-N 0.000 description 2
- RDFRSUBQYIZKSW-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C RDFRSUBQYIZKSW-UHFFFAOYSA-N 0.000 description 2
- CDEYNSJIONMJNM-UHFFFAOYSA-N 6-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound [Si](C)(C)(C(C)(C)C)OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C CDEYNSJIONMJNM-UHFFFAOYSA-N 0.000 description 2
- MWVLKXHKJCENJR-UHFFFAOYSA-N 8-(2-hydroxyethyl)-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound OCCN1C(C(=CC2=C1N=C(N=C2)SC)C1=CC=CC=C1)=O MWVLKXHKJCENJR-UHFFFAOYSA-N 0.000 description 2
- YSMOECQOOXGKLY-UHFFFAOYSA-N 8-(2-hydroxyethyl)-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound OCCN1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=CC=CC=C1)=O YSMOECQOOXGKLY-UHFFFAOYSA-N 0.000 description 2
- REFHEVHRVYBOJF-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-imine Chemical compound N=C1N(C)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 REFHEVHRVYBOJF-UHFFFAOYSA-N 0.000 description 2
- YYOFUULRDCRFOA-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 YYOFUULRDCRFOA-UHFFFAOYSA-N 0.000 description 2
- AYYAGZHKFLLINM-UHFFFAOYSA-N 8-methyl-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1 AYYAGZHKFLLINM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- NFGHJQWPDKIDRW-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=N)C Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=N)C NFGHJQWPDKIDRW-UHFFFAOYSA-N 0.000 description 2
- HQPDRQRHVLPUTB-UHFFFAOYSA-N ClC1=C(C=CC=C1)C=1C(N(C2=CC(=NC=C2C=1)NC1=CC(=CC=C1)N1CCS(CC1)(=O)=O)C)=O Chemical compound ClC1=C(C=CC=C1)C=1C(N(C2=CC(=NC=C2C=1)NC1=CC(=CC=C1)N1CCS(CC1)(=O)=O)C)=O HQPDRQRHVLPUTB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- PCDXCIMROXIFBI-UHFFFAOYSA-N ethyl 2-chloro-2-diethoxyphosphorylacetate Chemical compound CCOC(=O)C(Cl)P(=O)(OCC)OCC PCDXCIMROXIFBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- IUUDCMFVEMKOBT-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)formamide Chemical compound CS(=O)(=O)C1=CC=C(NC=O)C=C1 IUUDCMFVEMKOBT-UHFFFAOYSA-N 0.000 description 2
- CBKFHSNATJJWQK-UHFFFAOYSA-N n-pyridin-3-ylformamide Chemical compound O=CNC1=CC=CN=C1 CBKFHSNATJJWQK-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical group N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- XLVOWGDFXAVSFE-UHFFFAOYSA-N (4-amino-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(N)=N1 XLVOWGDFXAVSFE-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- LHHZRIYUOZPKSG-UHFFFAOYSA-N 1-(3-nitrophenyl)piperazine Chemical compound [O-][N+](=O)C1=CC=CC(N2CCNCC2)=C1 LHHZRIYUOZPKSG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CWORZSMRYNSMCN-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-6-(4-hydroxyphenyl)-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=C(C=C1)O)=O)C)CC CWORZSMRYNSMCN-UHFFFAOYSA-N 0.000 description 1
- RXINECZBKGCLEK-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-6-(4-methoxyphenyl)-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=C(C=C1)OC)=O)C)CC RXINECZBKGCLEK-UHFFFAOYSA-N 0.000 description 1
- AOFHPWKDAJCJHE-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-(2-hydroxyethyl)-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=CC=C1)=O)CCO)CC AOFHPWKDAJCJHE-UHFFFAOYSA-N 0.000 description 1
- XGUIEYMNFRMLPV-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C=CC=CC=2)C(=O)N2C)C2=N1 XGUIEYMNFRMLPV-UHFFFAOYSA-N 0.000 description 1
- ZJAVZNSTYFVSAG-UHFFFAOYSA-N 2-methylsulfanyl-6-phenyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound OC1=NC2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 ZJAVZNSTYFVSAG-UHFFFAOYSA-N 0.000 description 1
- CLEJJQVWLKAXSW-UHFFFAOYSA-N 3-(2-chlorophenyl)-1-methyl-7-(3-methylsulfonylanilino)-1,6-naphthyridin-2-one Chemical compound CN1C(=O)C(=CC2=C1C=C(NC1=CC(=CC=C1)S(C)(=O)=O)N=C2)C1=C(Cl)C=CC=C1 CLEJJQVWLKAXSW-UHFFFAOYSA-N 0.000 description 1
- FTFIOISFLMJDME-UHFFFAOYSA-N 3-(2-chlorophenyl)-1-methyl-7-(3-piperazin-1-ylanilino)-1,6-naphthyridin-2-one Chemical compound CN1C(=O)C(=CC2=C1C=C(NC1=CC(=CC=C1)N1CCNCC1)N=C2)C1=C(Cl)C=CC=C1 FTFIOISFLMJDME-UHFFFAOYSA-N 0.000 description 1
- MOKUOUWCNDXCEE-UHFFFAOYSA-N 3-(2-chlorophenyl)-1-methyl-7-[(5-piperazin-1-ylpyridin-3-yl)amino]-1,6-naphthyridin-2-one Chemical compound CN1C(=O)C(=CC2=C1C=C(NC1=CC(=CN=C1)N1CCNCC1)N=C2)C1=C(Cl)C=CC=C1 MOKUOUWCNDXCEE-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- MBNPJRQKQLLRIS-UHFFFAOYSA-N 3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(N)=C1 MBNPJRQKQLLRIS-UHFFFAOYSA-N 0.000 description 1
- FSVYGMJRBWRMFH-UHFFFAOYSA-N 4-[2-(3-methylsulfonylanilino)quinazolin-6-yl]phenol Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C1=CC=C(C=C1)O FSVYGMJRBWRMFH-UHFFFAOYSA-N 0.000 description 1
- WJDFQVQZUNCBGA-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C WJDFQVQZUNCBGA-UHFFFAOYSA-N 0.000 description 1
- VBZODFGFKXFBLY-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C VBZODFGFKXFBLY-UHFFFAOYSA-N 0.000 description 1
- PJXOTIYEIKVEGR-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C PJXOTIYEIKVEGR-UHFFFAOYSA-N 0.000 description 1
- LATMRUSMLRSPOU-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C LATMRUSMLRSPOU-UHFFFAOYSA-N 0.000 description 1
- DHLDFZDYTZKHEN-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C DHLDFZDYTZKHEN-UHFFFAOYSA-N 0.000 description 1
- SBTAGVYSJMZSQE-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C SBTAGVYSJMZSQE-UHFFFAOYSA-N 0.000 description 1
- QXZQWTRSWYLAFO-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C QXZQWTRSWYLAFO-UHFFFAOYSA-N 0.000 description 1
- VNJSERLEIJDSJV-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C VNJSERLEIJDSJV-UHFFFAOYSA-N 0.000 description 1
- JNKUZYYVHRNNPG-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methylpropyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC(C)C JNKUZYYVHRNNPG-UHFFFAOYSA-N 0.000 description 1
- BFHYOBKLKHMXFZ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methylpropyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC(C)C BFHYOBKLKHMXFZ-UHFFFAOYSA-N 0.000 description 1
- GHIRKOYLRMQNAF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C GHIRKOYLRMQNAF-UHFFFAOYSA-N 0.000 description 1
- JTWDQFJHOKLOHG-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-(4-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)S(=O)(=O)C)N(C1=O)C JTWDQFJHOKLOHG-UHFFFAOYSA-N 0.000 description 1
- ALEALKZBRLEOJZ-UHFFFAOYSA-N 6-(2-chlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C ALEALKZBRLEOJZ-UHFFFAOYSA-N 0.000 description 1
- CNHAKFYAPGFFRH-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C CNHAKFYAPGFFRH-UHFFFAOYSA-N 0.000 description 1
- YMCJVINRUYZBOB-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(3-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)N2CCNCC2)N(C1=O)C YMCJVINRUYZBOB-UHFFFAOYSA-N 0.000 description 1
- CJNSVBCBWCPNMO-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=NC=CC=C2)N(C1=O)C CJNSVBCBWCPNMO-UHFFFAOYSA-N 0.000 description 1
- JXODUKPTDVRVRW-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(pyridin-3-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC=2C=NC=CC=2)N(C1=O)C JXODUKPTDVRVRW-UHFFFAOYSA-N 0.000 description 1
- HMHLUVLAKOYBNP-UHFFFAOYSA-N 6-(2-chlorophenyl)-N-(3-methylsulfonylphenyl)quinazolin-2-amine Chemical compound ClC1=C(C=CC=C1)C=1C=C2C=NC(=NC2=CC=1)NC1=CC(=CC=C1)S(=O)(=O)C HMHLUVLAKOYBNP-UHFFFAOYSA-N 0.000 description 1
- QDPCSLVQTXXDET-UHFFFAOYSA-N 6-(2-chlorophenyl)-N-[4-[2-(diethylamino)ethoxy]phenyl]quinazolin-2-amine Chemical compound ClC1=C(C=CC=C1)C=1C=C2C=NC(=NC2=CC=1)NC1=CC=C(C=C1)OCCN(CC)CC QDPCSLVQTXXDET-UHFFFAOYSA-N 0.000 description 1
- BKKLKDBGZYFYHB-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C BKKLKDBGZYFYHB-UHFFFAOYSA-N 0.000 description 1
- IWKOGJYABSALSF-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)CC(C)C IWKOGJYABSALSF-UHFFFAOYSA-N 0.000 description 1
- XIXAMNAQPOFORK-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C XIXAMNAQPOFORK-UHFFFAOYSA-N 0.000 description 1
- YISXPUJRNVVHRT-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C YISXPUJRNVVHRT-UHFFFAOYSA-N 0.000 description 1
- GTFQUQGCWGESDG-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound COC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C GTFQUQGCWGESDG-UHFFFAOYSA-N 0.000 description 1
- LXFRLBOLLMEJTK-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C LXFRLBOLLMEJTK-UHFFFAOYSA-N 0.000 description 1
- LRADTRCBCZVNHT-UHFFFAOYSA-N 6-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound [Si](C)(C)(C(C)(C)C)OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C LRADTRCBCZVNHT-UHFFFAOYSA-N 0.000 description 1
- KQVQQSLYBUVFRU-UHFFFAOYSA-N 6-chloro-4-(methylamino)pyridine-3-carboxylic acid Chemical compound CNC1=CC(Cl)=NC=C1C(O)=O KQVQQSLYBUVFRU-UHFFFAOYSA-N 0.000 description 1
- KWZMLARYZJWIGD-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C1=CC=CC=C1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC=C(C=C1)OCCN(CC)CC)C1=C(C=CC=C1Cl)Cl)=O KWZMLARYZJWIGD-UHFFFAOYSA-N 0.000 description 1
- MOBSPJDIUFOWRW-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound CSc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(Cc3ccccc3)c2n1 MOBSPJDIUFOWRW-UHFFFAOYSA-N 0.000 description 1
- MCUZSPMYZFXONZ-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C1=CC=CC=C1)N1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=C(C=CC=C1Cl)Cl)=O MCUZSPMYZFXONZ-UHFFFAOYSA-N 0.000 description 1
- ZEAGCABTPLPQOS-UHFFFAOYSA-N 8-ethyl-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 ZEAGCABTPLPQOS-UHFFFAOYSA-N 0.000 description 1
- VZRSUDPBMFMEEH-UHFFFAOYSA-N 8-ethyl-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1 VZRSUDPBMFMEEH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JUDOSMOOLQAAQD-UHFFFAOYSA-N N-(3-methylsulfonylphenyl)-6-pyridin-2-ylquinazolin-2-amine Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C1=NC=CC=C1 JUDOSMOOLQAAQD-UHFFFAOYSA-N 0.000 description 1
- USZMUEBWKFFRMB-UHFFFAOYSA-N N-(3-methylsulfonylphenyl)-6-pyridin-3-ylquinazolin-2-amine Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C=1C=NC=CC=1 USZMUEBWKFFRMB-UHFFFAOYSA-N 0.000 description 1
- 108700011067 Necrosome Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 101710092490 Protein kinase 3 Proteins 0.000 description 1
- 101150025038 RIPK3 gene Proteins 0.000 description 1
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 1
- 102000013070 Receptor-Interacting Protein Serine-Threonine Kinase 2 Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NXNGLEYSIAXGCL-UHFFFAOYSA-N [4-(methylamino)-2-methylsulfanylpyrimidin-5-yl]methanol Chemical compound CNC1=NC(SC)=NC=C1CO NXNGLEYSIAXGCL-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 description 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- AAUBVINEXCCXOK-UHFFFAOYSA-N ethyl 4,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1Cl AAUBVINEXCCXOK-UHFFFAOYSA-N 0.000 description 1
- 229940064982 ethylnicotinate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000054953 human ACVR1 Human genes 0.000 description 1
- 102000050354 human NOD2 Human genes 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KHBWTRFWQROKJZ-UHFFFAOYSA-N methyl 2-(2-chlorophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1Cl KHBWTRFWQROKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ZLZZAXUKBHFTHA-UHFFFAOYSA-N n,n-diethyl-2-(4-nitrophenoxy)ethanamine Chemical compound CCN(CC)CCOC1=CC=C([N+]([O-])=O)C=C1 ZLZZAXUKBHFTHA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DUTLKLPXMPHUMV-UHFFFAOYSA-N tert-butyl 4-(3-nitrophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC([N+]([O-])=O)=C1 DUTLKLPXMPHUMV-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024145040A JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848719P | 2019-05-16 | 2019-05-16 | |
| US201962848648P | 2019-05-16 | 2019-05-16 | |
| US62/848,648 | 2019-05-16 | ||
| US62/848,719 | 2019-05-16 | ||
| PCT/US2020/032784 WO2020232190A1 (en) | 2019-05-16 | 2020-05-14 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024145040A Division JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533182A JP2022533182A (ja) | 2022-07-21 |
| JPWO2020232190A5 JPWO2020232190A5 (enExample) | 2023-05-02 |
| JP7546603B2 true JP7546603B2 (ja) | 2024-09-06 |
Family
ID=70919255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568650A Active JP7546603B2 (ja) | 2019-05-16 | 2020-05-14 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
| JP2024145040A Pending JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024145040A Pending JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220194937A1 (enExample) |
| EP (2) | EP4480485A3 (enExample) |
| JP (2) | JP7546603B2 (enExample) |
| AU (1) | AU2020275304B2 (enExample) |
| CA (1) | CA3137869A1 (enExample) |
| WO (1) | WO2020232190A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024170457A (ja) * | 2019-05-16 | 2024-12-10 | ユニバーシティー オブ ヒューストン システム | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11174255B2 (en) * | 2017-05-15 | 2021-11-16 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases |
| CN113072471B (zh) * | 2021-03-02 | 2022-09-16 | 四川美大康华康药业有限公司 | 一种利非司特中间体及其制备方法 |
| WO2024097805A1 (en) * | 2022-11-01 | 2024-05-10 | Trustees Of Tufts College | Mixed lineage kinase domain like pseudokinase (mlkl) activators |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001515078A (ja) | 1997-08-20 | 2001-09-18 | ワーナー−ランバート・カンパニー | プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン |
| JP2003523358A (ja) | 2000-01-27 | 2003-08-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 神経変性疾患の治療のためのピリドピリミジノン誘導体 |
| WO2014031571A1 (en) | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| WO2015179436A1 (en) | 2014-05-19 | 2015-11-26 | Sanford-Burnham Medical Research Institute | Inflammation therapy using mekk3 inhibitors or blocking peptides |
| WO2018213219A1 (en) | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US20220194937A1 (en) * | 2019-05-16 | 2022-06-23 | University Of Houston System | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
-
2020
- 2020-05-14 US US17/595,406 patent/US20220194937A1/en active Pending
- 2020-05-14 EP EP24191377.1A patent/EP4480485A3/en active Pending
- 2020-05-14 JP JP2021568650A patent/JP7546603B2/ja active Active
- 2020-05-14 AU AU2020275304A patent/AU2020275304B2/en active Active
- 2020-05-14 WO PCT/US2020/032784 patent/WO2020232190A1/en not_active Ceased
- 2020-05-14 CA CA3137869A patent/CA3137869A1/en active Pending
- 2020-05-14 EP EP20729566.8A patent/EP3968991B1/en active Active
-
2024
- 2024-08-27 JP JP2024145040A patent/JP2024170457A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001515078A (ja) | 1997-08-20 | 2001-09-18 | ワーナー−ランバート・カンパニー | プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン |
| JP2003523358A (ja) | 2000-01-27 | 2003-08-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 神経変性疾患の治療のためのピリドピリミジノン誘導体 |
| WO2014031571A1 (en) | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| WO2015179436A1 (en) | 2014-05-19 | 2015-11-26 | Sanford-Burnham Medical Research Institute | Inflammation therapy using mekk3 inhibitors or blocking peptides |
| WO2018213219A1 (en) | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
Non-Patent Citations (1)
| Title |
|---|
| THOMPSON,A.M. et al.，Synthesis and Structure-Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as Selective Inhibitors of pp60c-src，Journal of Medicinal Chemistry，2000年，Vol.43, No.16，p.3134-3147 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024170457A (ja) * | 2019-05-16 | 2024-12-10 | ユニバーシティー オブ ヒューストン システム | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020275304A1 (en) | 2021-12-16 |
| JP2024170457A (ja) | 2024-12-10 |
| WO2020232190A1 (en) | 2020-11-19 |
| EP3968991C0 (en) | 2024-07-31 |
| EP4480485A3 (en) | 2025-02-26 |
| US20220194937A1 (en) | 2022-06-23 |
| CA3137869A1 (en) | 2020-11-19 |
| JP2022533182A (ja) | 2022-07-21 |
| EP3968991A1 (en) | 2022-03-23 |
| AU2020275304B2 (en) | 2025-01-23 |
| EP3968991B1 (en) | 2024-07-31 |
| EP4480485A2 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7546603B2 (ja) | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CN109071514B (zh) | 用作蛋白质调节剂的杂环酰胺 | |
| TWI433677B (zh) | 雜環化合物及其用途 | |
| TWI659021B (zh) | Ｋｒａｓ ｇ１２ｃ之抑制劑 | |
| US9567342B2 (en) | Certain protein kinase inhibitors | |
| AU2021282986B2 (en) | LPA receptor antagonists and uses thereof | |
| WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
| CN106488910A (zh) | Kras g12c的抑制剂 | |
| RS63603B1 (sr) | Sredstva za indukciju apoptoze | |
| CN105555786A (zh) | 作为BET蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮 | |
| CN110603256A (zh) | 可用作wee-1激酶抑制剂的嘧啶并嘧啶酮 | |
| CN100439365C (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| CN110461837B (zh) | 新型吡咯并吡啶衍生物、其制备方法及用途 | |
| US20240327403A1 (en) | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | |
| CN110997657A (zh) | 咪唑烷化合物 | |
| CN106146493A (zh) | 吡唑并[3,4-b]吡啶类和吲唑类化合物的制备方法和用途 | |
| KR20150103672A (ko) | 나프티리디논 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도 | |
| TW201712011A (zh) | 作為ｂｅｔ家族溴結構域抑制劑之新穎吡啶吡酮 | |
| WO2020114519A1 (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
| WO2015193228A1 (de) | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe | |
| CN111205281B (zh) | 杂环化合物及其用途 | |
| JP2024536861A (ja) | 伝染性軟属腫感染症の阻害剤およびそれを用いる方法 | |
| KR20240115270A (ko) | 사이클린 의존성 키나아제의 새로운 억제제 | |
| HK40082693B (zh) | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230424 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240523 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240724 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240827 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7546603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |